GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Cyclically Adjusted Revenue per Share

Evotec SE (Evotec SE) Cyclically Adjusted Revenue per Share : $1.55 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Evotec SE's adjusted revenue per share for the three months ended in Dec. 2023 was $0.620. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.55 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Evotec SE's average Cyclically Adjusted Revenue Growth Rate was 14.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Evotec SE was 23.00% per year. The lowest was 20.80% per year. And the median was 22.60% per year.

As of today (2024-05-02), Evotec SE's current stock price is $5.33. Evotec SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.55. Evotec SE's Cyclically Adjusted PS Ratio of today is 3.44.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evotec SE was 25.77. The lowest was 3.27. And the median was 16.45.


Evotec SE Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Evotec SE's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Cyclically Adjusted Revenue per Share Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.97 1.10 1.31 1.55

Evotec SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.31 1.44 1.43 1.55

Competitive Comparison of Evotec SE's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's Cyclically Adjusted PS Ratio falls into.



Evotec SE Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evotec SE's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.62/123.6675*123.6675
=0.620

Current CPI (Dec. 2023) = 123.6675.

Evotec SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.135 99.356 0.168
201403 0.093 99.543 0.116
201406 0.116 99.543 0.144
201409 0.092 99.823 0.114
201412 0.143 99.543 0.178
201503 0.089 99.717 0.110
201506 0.143 100.417 0.176
201509 0.142 100.417 0.175
201512 0.138 99.717 0.171
201603 0.158 100.017 0.195
201606 0.161 100.717 0.198
201609 0.191 101.017 0.234
201612 0.174 101.217 0.213
201703 0.195 101.417 0.238
201706 0.205 102.117 0.248
201709 0.275 102.717 0.331
201712 0.370 102.617 0.446
201803 0.342 102.917 0.411
201806 0.386 104.017 0.459
201809 0.393 104.718 0.464
201812 0.374 104.217 0.444
201903 0.393 104.217 0.466
201906 0.390 105.718 0.456
201909 0.420 106.018 0.490
201912 0.462 105.818 0.540
202003 0.437 105.718 0.511
202006 0.416 106.618 0.483
202009 0.505 105.818 0.590
202012 0.528 105.518 0.619
202103 0.483 107.518 0.556
202106 0.507 108.486 0.578
202109 0.571 109.435 0.645
202112 0.612 110.384 0.686
202203 0.513 113.968 0.557
202206 0.515 115.760 0.550
202209 0.487 118.818 0.507
202212 0.722 119.345 0.748
202306 0.521 123.140 0.523
202309 0.592 124.195 0.589
202312 0.620 123.668 0.620

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Evotec SE  (NAS:EVO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Evotec SE's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.33/1.55
=3.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evotec SE was 25.77. The lowest was 3.27. And the median was 16.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Evotec SE Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Evotec SE's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (Evotec SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Cyclically Adjusted Revenue per Share
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.